CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

NCT01454596 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

NIH

Sponsor class

Conditions

Malignant Glioma
Glioblastoma
Brain Cancer
Gliosarcoma

Interventions

BIOLOGICAL: Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL
DRUG: Aldesleukin
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

National Cancer Institute (NCI)